(Q53184936)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

main subject

metastatic breast cancer

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Veronique Edeline

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Olivier Madar

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Nina Mortazavi-Jehanno

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Anne-Laure Giraudet

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Florence Lerebours

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Elise Le Stanc

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Dominique Bellet

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Alain Paul Pecking

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jean-Louis Alberini

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

20 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

number of pages

11

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

450-460

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00259-011-1981-z

19 January 2020

exact match

0 references

cites work

Third consensus on medical treatment of metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Monitoring primary breast cancer throughout chemotherapy using FDG-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Metabolic flare: indicator of hormone responsiveness in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Bone imaging in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Breast cancer: PET imaging of estrogen receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

17beta-estradiol augments 18F-FDG uptake and glycolysis of T47D breast cancer cells via membrane-initiated rapid PI3K-Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1981-Z

The relationship between FDG uptake in PET scans and biological behavior in breast cancer

21 January 2018

1 reference

12 December 2020

Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy

1 reference

12 December 2020

Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer

1 reference

12 December 2020

Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.

1 reference

12 December 2020

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy

1 reference

12 December 2020

Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.

1 reference

12 December 2020

Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma.

1 reference

12 December 2020

Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management

1 reference

12 December 2020

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer

1 reference

12 December 2020

Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer

1 reference

12 December 2020

10.1007/S00259-011-1981-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22183107%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference